A crash for the markets - a crash for biotechs ? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A crash for the markets - a crash for biotechs ?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: trevor john wilkinson who wrote ()	1/6/1997 8:31:00 PM
From: ping quin	of 74

Is $.70 per share a good buy ($14 million market cap.) for a startup drug discovery company that is conducting clinical phase 1 trial for its potential "blockbuster" drugs in antiarrhythmics? They prefer to use "pathology targeting" for drug discovery instead of "molecular targeting". The company is called Nortran Pharmaceuticals Inc., a University of BC spinoff , and currently listed on Vancouver Stock Exchange under NRT. Anybody following this? Any suggestions? nortran.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next